Agreements

Antitope has announced a Research Agreement with Research Corporation Technologies, (\"RCT\") to re-engineer a toxic protein warhead for the next generation of antibody-drug-conjugates (ADCs) using its proprietary Composite Protein™ technology. The resulting “deimmunised” protein is expected to have a range of therapeutic applications especially in treatment of cancers.

Antitope Ltd. is a privately-held Cambridge, UK-based biotechnology company specialising in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope’s proprietary EpiScreen™ technology enables preclinical analysis of the potential for immunogenicity of therapeutic antibodies and proteins. The proprietary Composite Human Antibody™ and Composite Protein™ technologies result in the generation of fully humanised antibodies and therapeutic proteins devoid of T cell epitopes. Antitope\'s proprietary Composite CHO™ technology results in the generation of high yielding manufacturing cell lines suitable for direct transfer to GMP manufacture. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide.